{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:27:00Z","timestamp":1791404820510,"version":"4.3.3"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R268-2016-3925"],"award-info":[{"award-number":["R268-2016-3925"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R278-2018-1411"],"award-info":[{"award-number":["R278-2018-1411"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["7025-00078B"],"award-info":[{"award-number":["7025-00078B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["9088-00002B"],"award-info":[{"award-number":["9088-00002B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbi.2020.08.028","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T21:05:40Z","timestamp":1599080740000},"page":"364-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders \u2013 A comprehensive systematic review and meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Rose","family":"Jeppesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune H.B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie M.J.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Nordentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Hjorth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"K\u00f6hler-Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Benros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0278-5846(03)00161-1","article-title":"Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial","volume":"27","author":"Akhondzadeh","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiat."},{"issue":"1\u20133","key":"10.1016\/j.bbi.2020.08.028_b0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0015","doi-asserted-by":"crossref","unstructured":"Attari A, Mojdeh A, Khalifeh Soltani FAS, Najarzadegan MR. 2016. Aspirin Inclusion in Antipsychotic Treatment on Severity of Symptoms in Schizophrenia: A Randimized Clinical Trial. Iran J. Psychiatry Behav. Sci. In Press(In Press). doi:10.17795\/ijpbs-5848.","DOI":"10.17795\/ijpbs-5848"},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpsychires.2009.08.008","article-title":"Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood\u2013CSF barrier dysfunction","volume":"44","author":"Bechter","year":"2010","journal-title":"J. Psychiatr. Res."},{"issue":"2\u20133","key":"10.1016\/j.bbi.2020.08.028_b0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2012.08.016","article-title":"Estrogen augmentation in schizophrenia: a quantitative review of current evidence","volume":"141","author":"Begemann","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jad.2018.11.086","article-title":"Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice","volume":"245","author":"Ben","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","article-title":"Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study","volume":"168","author":"Benros","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0040","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/tp.2013.110","article-title":"A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia","volume":"3","author":"Bentsen","year":"2013","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: From malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.bbi.2020.08.028_b0050","doi-asserted-by":"crossref","unstructured":"Berger GE, Proffitt T-M, McConchie M, 2007. et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry. 68(12):1867-1875. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18162017. Accessed August 8, 2018.","DOI":"10.4088\/JCP.v68n1206"},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia\u2014A Double-Blind, Randomized, Placebo-Controlled Trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry."},{"issue":"4","key":"10.1016\/j.bbi.2020.08.028_b0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1179\/1476830514Y.0000000139","article-title":"Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol","volume":"19","author":"Bo\u0161kovi\u0107","year":"2016","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.bbi.2020.08.028_b0065","doi-asserted-by":"crossref","unstructured":"Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006, 2(4):531-536. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19412501. Accessed August 15, 2018.","DOI":"10.2147\/nedt.2006.2.4.531"},{"key":"10.1016\/j.bbi.2020.08.028_b0070","unstructured":"Breier A., 2019. Fingolimod in Schizophrenia Patients (STEP). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01779700."},{"key":"10.1016\/j.bbi.2020.08.028_b0075","doi-asserted-by":"crossref","unstructured":"Breier A, Liffick E, Hummer TA, et al. 2018. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. March <xocs:firstpage xmlns:xocs. doi:10.1016\/j.schres.2018.03.012.","DOI":"10.1016\/j.schres.2018.03.012"},{"key":"10.1016\/j.bbi.2020.08.028_b0080","unstructured":"Breier A. 2019. The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia (Beta). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01874756."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","article-title":"Mechanisms for the anti-inflammatory effects of statins","volume":"22","author":"Bu","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.bbi.2020.08.028_b0090","unstructured":"Buchanan RW. 2018. Anti-Inflammatory Treatment of Schizophrenia - ClinicalTrials.gov NCT01514682. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01514682?sect=Xbc0156. Accessed August 13."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0447.2007.00992.x","article-title":"Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?","volume":"115","author":"Buckley","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbi.2020.08.028_b0100","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","author":"\u00c7akici","year":"2019","journal-title":"Psychol. Med."},{"issue":"9","key":"10.1016\/j.bbi.2020.08.028_b0105","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbi.2020.08.028_b0110","doi-asserted-by":"crossref","unstructured":"Chen AT, Chibnall JT, Nasrallah HA. 2015. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Ann. Clin. Psychiatry 27(4):289-296. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26554370. Accessed September 21, 2018.","DOI":"10.1177\/104012371502700408"},{"issue":"4","key":"10.1016\/j.bbi.2020.08.028_b0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lfs.2007.05.023","article-title":"Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury","volume":"81","author":"Chen","year":"2007","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.bbi.2020.08.028_b0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0125","first-page":"1103","article-title":"Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-\u03baB and inhibition of HDAC1 and the PI3K\/Akt\/mTOR pathway in RAW264.7 macrophages","volume":"41","author":"Choi","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbi.2020.08.028_b0130","unstructured":"Cohen J. 1988. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale N.J.: L. Erlbaum Associates. https:\/\/www.worldcat.org\/title\/statistical-power-analysis-for-the-behavioral-sciences\/oclc\/17877467. Accessed March 18, 2019."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/schbul\/sbx093","article-title":"N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis","volume":"44","author":"Conus","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2020.08.028_b0140","unstructured":"R Core Team. 2018. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.r-project.org\/. Published."},{"issue":"Supplement 1","key":"10.1016\/j.bbi.2020.08.028_b0145","first-page":"S308","article-title":"Randomized controlled trial of N-acetylcysteine for cognition and EEG correlates in schizophrenia","volume":"41","author":"Davis","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2020.08.028_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-017-0043-3","article-title":"The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis","author":"de Boer","year":"2018","journal-title":"npj Schizophr."},{"issue":"11","key":"10.1016\/j.bbi.2020.08.028_b0155","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","article-title":"The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Deakin","year":"2018","journal-title":"Lancet Psych."},{"issue":"11","key":"10.1016\/j.bbi.2020.08.028_b0160","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbi.2020.08.028_b0165","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3802833. Accessed March 1, 2019.","DOI":"10.1016\/0197-2456(86)90046-2"},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00004714-200210000-00011","article-title":"Controlled Trial of Hydroxychloroquine in Schizophrenia","volume":"22","author":"Desta","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010054022079","article-title":"Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: Their role in inflammatory, allergic and immunological disorders","volume":"4","author":"Dillon","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"10.1016\/j.bbi.2020.08.028_b0180","doi-asserted-by":"crossref","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. 2019. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315(7109):629-634. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9310563. Accessed March 1.","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"9","key":"10.1016\/j.bbi.2020.08.028_b0185","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1176\/appi.ajp.159.9.1596","article-title":"Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia","volume":"159","author":"Emsley","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","article-title":"The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial","volume":"84","author":"Emsley","year":"2006","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.bbi.2020.08.028_b0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2014.06.004","article-title":"A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia","volume":"158","author":"Emsley","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2015.00476","article-title":"Immunological findings in psychotic syndromes: a tertiary care hospital\u2019s CSF sample of 180 patients","volume":"9","author":"Endres","year":"2015","journal-title":"Front. Hum. Neurosci."},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","article-title":"N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia","volume":"36","author":"Farokhnia","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0210","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/appi.ajp.158.12.2071","article-title":"A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia","volume":"158","author":"Fenton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2020.08.028_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155631","article-title":"Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia. Boussiotis VA, ed","author":"Fernandez-Egea","year":"2016","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/1872213X08666140623114845","article-title":"Modulatory Effects of Peroxisome Proliferator-Activated Receptor-\u03b3 on CXCR3 Chemokines","volume":"8","author":"Ferrari","year":"2015","journal-title":"Recent Pat Inflamm. Allergy Drug Discov."},{"issue":"7","key":"10.1016\/j.bbi.2020.08.028_b0225","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.euroneuro.2014.03.001","article-title":"Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study","volume":"24","author":"Fervaha","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.bbi.2020.08.028_b0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","article-title":"Impact of primary negative symptoms on functional outcomes in schizophrenia","volume":"29","author":"Fervaha","year":"2014","journal-title":"Eur Psychiatry."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0b013e318248b7bb","article-title":"Eicosapentaenoic Acid Interventions in Schizophrenia","volume":"32","author":"Fusar-Poli","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2012.10.006","article-title":"What is behind the non-antibiotic properties of minocycline?","volume":"67","author":"Garrido-Mesa","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.bbi.2020.08.028_b0245","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3371\/CSRP.GHFA.01062013","article-title":"Combination of Estrogen and Antipsychotics in the Treatment of Women with Chronic Schizophrenia","volume":"6","author":"Ghafari","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses."},{"key":"10.1016\/j.bbi.2020.08.028_b0250","doi-asserted-by":"crossref","unstructured":"Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M, Rezaei Z. 2014. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov. 8(3):211-215. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25353174. Accessed August 7, 2018.","DOI":"10.2174\/1872213X08666141029123524"},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0255","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.psychres.2014.06.039","article-title":"Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial","volume":"219","author":"Ghanizadeh","year":"2014","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0260","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/npp.2017.258","article-title":"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia","volume":"43","author":"Girgis","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2020.08.028_b0265","doi-asserted-by":"crossref","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ. 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. In: Mol. Psychiatry Vol 21, 1696-1709. doi:10.1038\/mp.2016.3.","DOI":"10.1038\/mp.2016.3"},{"issue":"1\u20132","key":"10.1016\/j.bbi.2020.08.028_b0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0275","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.expneurol.2004.06.008","article-title":"Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury","volume":"189","author":"He","year":"2004","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3102\/10769986006002107","article-title":"Distribution Theory for Glass\u2019s Estimator of Effect size and Related Estimators","volume":"6","author":"Hedges","year":"1981","journal-title":"J Educ Stat."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0285","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1037\/0033-2909.92.2.490","article-title":"Estimation of effect size from a series of independent experiments","volume":"92","author":"Hedges","year":"1982","journal-title":"Psychol. Bull."},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0290","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0447.2008.01325.x","article-title":"A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia","volume":"119","author":"Henderson","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0295","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.schres.2015.04.002","article-title":"Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review","volume":"168","author":"Heringa","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0300","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011, 343(oct18 2):d5928-d5928. doi:10.1136\/bmj.d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"10.1016\/j.bbi.2020.08.028_b0305","doi-asserted-by":"crossref","unstructured":"Higgins J.P.T., Green S., Sally E, 2008Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell.","DOI":"10.1002\/9780470712184"},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2011.11.021","article-title":"Aspirin and immune system","volume":"12","author":"Hussain","year":"2012","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.2517","article-title":"The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial","volume":"31","author":"Iranpour","year":"2016","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.bbi.2020.08.028_b0320","doi-asserted-by":"crossref","unstructured":"Ishihara T, Yoshida M, Arita M. 2019. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis - PubMed. Int. Immunol., 31(9):559-567. https:\/\/pubmed.ncbi.nlm.nih.gov\/30772915\/. Accessed August 5, 2020.","DOI":"10.1093\/intimm\/dxz001"},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"issue":"7","key":"10.1016\/j.bbi.2020.08.028_b0330","doi-asserted-by":"crossref","DOI":"10.5539\/gjhs.v6n7p103","article-title":"Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia","volume":"6","author":"Jamilian","year":"2014","journal-title":"Glob J Health Sci."},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0335","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2741\/2802","article-title":"Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists","volume":"13","author":"Kapadia","year":"2008","journal-title":"Front. Biosci."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3371\/CSRP.KARA.070415","article-title":"Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"12","author":"Kardashev","year":"2018","journal-title":"Clin. Schizophr. Relat. Psychoses."},{"key":"10.1016\/j.bbi.2020.08.028_b0345","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpsychires.2017.06.011","article-title":"Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial","volume":"94","author":"Kashani","year":"2017","journal-title":"J. Psychiatr. Res."},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0350","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2020.08.028_b0355","doi-asserted-by":"crossref","unstructured":"Kelly DL, Sullivan KM, McEvoy JP, et al. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J. Clin. Psychopharmacol. June 2015:1. doi:10.1097\/JCP.0000000000000345.","DOI":"10.1016\/S0920-9964(14)70257-9"},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0360","first-page":"337","article-title":"A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia","volume":"53","author":"Khodaie-Ardakani","year":"2015","journal-title":"Acta Med. Iran."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0365","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.psychres.2013.12.051","article-title":"Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study","volume":"215","author":"Khodaie-Ardakani","year":"2014","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/2008-2231-22-55","article-title":"Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial","volume":"22","author":"Kianimehr","year":"2014","journal-title":"DARU J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0375","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-013-0047-0","article-title":"Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?","volume":"27","author":"Kucharska-Pietura","year":"2013","journal-title":"CNS Drugs."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0380","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0920-9964(00)00088-8","article-title":"Estrogen \u2014 a potential treatment for schizophrenia","volume":"48","author":"Kulkarni","year":"2001","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.bbi.2020.08.028_b0385","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/archpsyc.65.8.955","article-title":"Estrogen in Severe Mental Illness","volume":"65","author":"Kulkarni","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbi.2020.08.028_b0390","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.psyneuen.2010.01.014","article-title":"Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia","volume":"35","author":"Kulkarni","year":"2010","journal-title":"Psychoneuroendocrinology"},{"issue":"2\u20133","key":"10.1016\/j.bbi.2020.08.028_b0395","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.schres.2010.10.009","article-title":"Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?","volume":"125","author":"Kulkarni","year":"2011","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0400","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/mp.2014.33","article-title":"Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age","volume":"20","author":"Kulkarni","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.bbi.2020.08.028_b0405","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamapsychiatry.2016.1383","article-title":"Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women","volume":"73","author":"Kulkarni","year":"2016","journal-title":"JAMA Psychiatry."},{"issue":"05","key":"10.1016\/j.bbi.2020.08.028_b0410","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.bbi.2020.08.028_b0415","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.bbi.2020.08.028_b0420","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.schres.2012.01.014","article-title":"Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial","volume":"137","author":"Levine","year":"2012","journal-title":"Schizophr. Res."},{"issue":"02","key":"10.1016\/j.bbi.2020.08.028_b0425","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0430","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1\u20133","key":"10.1016\/j.bbi.2020.08.028_b0435","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2014.01.011","article-title":"Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial","volume":"153","author":"Liu","year":"2014","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.bbi.2020.08.028_b0440","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(03)00082-3","article-title":"Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study","volume":"66","author":"Louz\u00e3","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118690","article-title":"Internalization of particulate delivery systems by activated microglia influenced the therapeutic efficacy of simvastatin repurposing for neuroinflammation","volume":"570","author":"Manickavasagam","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbi.2020.08.028_b0450","unstructured":"Manteghiy A, Shakeri MT, Koohestani L, Salari E. 2008. Beneficial Antipsychotic Effects of Omega-3 Fatty Acids Add-on Therapy for the Pharmacological Management of Patients with Schizophrenia. Vol 2."},{"issue":"8","key":"10.1016\/j.bbi.2020.08.028_b0455","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/npp.2009.26","article-title":"Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia","volume":"34","author":"Marx","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/j.bbi.2020.08.028_b0460","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00213-014-3673-4","article-title":"Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia","volume":"231","author":"Marx","year":"2014","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0465","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbi.2020.08.028_b0470","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.taap.2018.03.005","article-title":"Differences in statin associated neuroprotection corresponds with either decreased production of IL-1\u03b2 or TNF-\u03b1 in an in vitro model of neuroinflammation-induced neurodegeneration","volume":"344","author":"McFarland","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbi.2020.08.028_b0475","doi-asserted-by":"crossref","unstructured":"McFarland A, Davey A, Anoopkumar-Dukie S. Statins 2017. Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells. Mediators Inflamm. 2017. https:\/\/www.hindawi.com\/journals\/mi\/2017\/2582745\/. Accessed August 5, 2020.","DOI":"10.1155\/2017\/2582745"},{"issue":"7","key":"10.1016\/j.bbi.2020.08.028_b0480","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0485","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpsychires.2014.02.013","article-title":"Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study","volume":"53","author":"Modabbernia","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.bbi.2020.08.028_b0490","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","article-title":"Pharmacological treatment of negative symptoms in schizophrenia","volume":"265","author":"M\u00f6ller","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0495","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00406-004-0478-1","article-title":"COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy","volume":"254","author":"M\u00fcller","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.bbi.2020.08.028_b0500","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"M\u00fcller","year":"2010","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0505","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1074\/jbc.RA118.005543","article-title":"The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation","volume":"294","author":"Murugan","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"sup1","key":"10.1016\/j.bbi.2020.08.028_b0510","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1080\/10408398.2018.1487927","article-title":"Anti-inflammatory effects of Melatonin: A mechanistic review","volume":"59","author":"Nabavi","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"2\u20133","key":"10.1016\/j.bbi.2020.08.028_b0515","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.schres.2005.07.029","article-title":"Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial","volume":"79","author":"Nachshoni","year":"2005","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0520","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2020.08.028_b0525","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.psychres.2017.11.033","article-title":"Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis","volume":"260","author":"Nomura","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0530","article-title":"Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis","author":"Orlovska-Waast","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0535","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hup.2426","article-title":"Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Oya","year":"2014","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.bbi.2020.08.028_b0540","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpsychires.2015.11.013","article-title":"A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia","volume":"73","author":"Pawe\u0142czyk","year":"2016","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0545","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0920-9964(00)00083-9","article-title":"Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia","volume":"49","author":"Peet","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0550","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2835787","article-title":"Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects","volume":"2018","author":"Pei","year":"2018","journal-title":"Oxid. Med. Cell Longev."},{"issue":"8","key":"10.1016\/j.bbi.2020.08.028_b0555","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","article-title":"Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review","volume":"38","author":"Plantone","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.bbi.2020.08.028_b0560","doi-asserted-by":"crossref","unstructured":"Prall SP, Muehlenbein MP. 2018. DHEA Modulates Immune Function: A Review of Evidence. In: Vitamins and Hormones. Vol 108. Academic Press Inc., 125-144. doi:10.1016\/bs.vh.2018.01.023.","DOI":"10.1016\/bs.vh.2018.01.023"},{"key":"10.1016\/j.bbi.2020.08.028_b0565","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2017.08.026","article-title":"Effects of Omega-3 in the treatment of violent schizophrenia patients","volume":"195","author":"Qiao","year":"2018","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0570","doi-asserted-by":"crossref","DOI":"10.3390\/nu11122990","article-title":"The influence of dietary fatty acids on immune responses","volume":"11","author":"Radzikowska","year":"2019","journal-title":"Nutrients."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0575","first-page":"31","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbi.2020.08.028_b0580","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.biopsych.2005.02.024","article-title":"Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia","volume":"57","author":"Rapaport","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2020.08.028_b0585","doi-asserted-by":"crossref","unstructured":"Reichenberg A, Reichenberg A (Avi). The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin Neurosci. 2010, 12(3):383-392. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20954432. Accessed August 9, 2018.","DOI":"10.31887\/DCNS.2010.12.3\/areichenberg"},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0590","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s11136-007-9195-3","article-title":"Predicting quality of life impairment in chronic schizophrenia from cognitive variables","volume":"16","author":"Ritsner","year":"2007","journal-title":"Qual. Life Res."},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0595","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.jcp.0000237942.50270.35","article-title":"Improvement of Sustained Attention and Visual and Movement Skills, but Not Clinical Symptoms, After Dehydroepiandrosterone Augmentation in Schizophrenia","volume":"26","author":"Ritsner","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.bbi.2020.08.028_b0600","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4088\/JCP.09m05031yel","article-title":"Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder","volume":"71","author":"Ritsner","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbi.2020.08.028_b0605","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/pcn.12150","article-title":"Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two-center trial","volume":"68","author":"Ritsner","year":"2014","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2020.08.028_b0610","article-title":"A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone","author":"Robinson","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.bbi.2020.08.028_b0615","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bdi.12196","article-title":"Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial","volume":"16","author":"Romo-Nava","year":"2014","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bbi.2020.08.028_b0620","unstructured":"Sayyah M, Boostani H, Ashrafpoori M, Pakseresht S. 2015. Effects of Atorvastatin on Negative Sign in Chronic Schizophrenia: a Double Blind Clinical Trial. Iran J. Pharm. Res. IJPR. 14(4):1269-1274. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26664396. Accessed August 8, 2018."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0625","first-page":"40","article-title":"An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News."},{"key":"10.1016\/j.bbi.2020.08.028_b0630","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pnpbp.2017.11.001","article-title":"Therapeutic effect of adjunctive N -acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial","volume":"82","author":"Sepehrmanesh","year":"2018","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"10.1016\/j.bbi.2020.08.028_b0635","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.psychres.2018.02.018","article-title":"Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications","volume":"262","author":"Shen","year":"2018","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0640","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.10.023","article-title":"Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study","volume":"143","author":"Smith","year":"2013","journal-title":"Schizophr. Res."},{"issue":"05","key":"10.1016\/j.bbi.2020.08.028_b0645","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1092852916000638","article-title":"Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia","volume":"22","author":"Solmi","year":"2017","journal-title":"CNS Spectr."},{"issue":"04","key":"10.1016\/j.bbi.2020.08.028_b0650","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4088\/JCP.10r06823","article-title":"Nonsteroidal Anti-Inflammatory Drugs in Schizophrenia","volume":"73","author":"Sommer","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0655","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0660","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","article-title":"Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A \u201ccentral hub\u201d in schizophrenia pathophysiology?","volume":"176","author":"Steullet","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0665","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psyneuen.2006.11.002","article-title":"Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial","volume":"32","author":"Strous","year":"2007","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0670","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00011-005-1343-z","article-title":"Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells","volume":"54","author":"Suuronen","year":"2005","journal-title":"Inflamm. Res."},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0675","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0000000000000159","article-title":"Simvastatin adjunct therapy for negative symptoms of schizophrenia","volume":"32","author":"Tajik-Esmaeeli","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.bbi.2020.08.028_b0680","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"Il-6 in inflammation, Immunity, And disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbi.2020.08.028_b0685","unstructured":"Tek C., 2014. A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia (NAC). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01232790."},{"issue":"1\u20132","key":"10.1016\/j.bbi.2020.08.028_b0690","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.imlet.2013.07.004","article-title":"Chloroquine: Modes of action of an undervalued drug","volume":"153","author":"Thom\u00e9","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bbi.2020.08.028_b0695","doi-asserted-by":"crossref","unstructured":"Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21(8):2580-2588. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11306611. Accessed August 2, 2018.","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001"},{"key":"10.1016\/j.bbi.2020.08.028_b0700","unstructured":"Tocilizumab - DrugBank. https:\/\/www.drugbank.ca\/drugs\/DB06273. Accessed August 5, 2020."},{"issue":"3","key":"10.1016\/j.bbi.2020.08.028_b0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030859","article-title":"Estrogen, angiogenesis, immunity and cell metabolism: Solving the puzzle","volume":"19","author":"Trenti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbi.2020.08.028_b0710","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","article-title":"Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation","volume":"76","author":"Tsai","year":"2016","journal-title":"Drugs."},{"issue":"11","key":"10.1016\/j.bbi.2020.08.028_b0715","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4088\/JCP.10m06610","article-title":"Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia","volume":"72","author":"Usall","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbi.2020.08.028_b0720","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/schbul\/sbv149","article-title":"Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial","volume":"42","author":"Usall","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.bbi.2020.08.028_b0725","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/er.2016-1007","article-title":"Estrogens, Neuroinflammation, and Neurodegeneration","volume":"37","author":"Villa","year":"2016","journal-title":"Endocr. Rev."},{"issue":"2\u20133","key":"10.1016\/j.bbi.2020.08.028_b0730","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2014.08.021","article-title":"A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism","volume":"159","author":"Vincenzi","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0735","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2020.08.028_b0740","doi-asserted-by":"crossref","unstructured":"Weickert T, Jacomb I, Lenroot R, et al. 2020. S318 Poster Session III S33. REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION S34. COGNITIVE HETEROGENEITY IN SCHIZOPHRENIA SPECTRUM DISORDERS: FINDINGS FROM A SYSTEMATIC REVIEW. https:\/\/academic.oup.com\/schizophreniabulletin\/article-abstract\/45\/Supplement_2\/S318\/5434457. Accessed March 13.","DOI":"10.1093\/schbul\/sbz020.578"},{"issue":"7","key":"10.1016\/j.bbi.2020.08.028_b0745","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.4088\/JCP.15m10498","article-title":"Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder","volume":"78","author":"Weiser","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2020.08.028_b0750","article-title":"The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial","author":"Weiser","year":"2018","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0755","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes","volume":"168","author":"Wykes","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2020.08.028_b0760","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euroneuro.2016.11.012","article-title":"Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials","volume":"27","author":"Xiang","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2020.08.028_b0765","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-008-8019-z","article-title":"Statins\u2019 immunomodulatory potential against Th17 cell-mediated autoimmune response","author":"Zhang","year":"2008","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0770","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2147\/NDT.S64236","article-title":"Profile of minocycline and its potential in the treatment of schizophrenia","volume":"10","author":"Zhang","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bbi.2020.08.028_b0775","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2018.04.004","article-title":"Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels","volume":"85","author":"Zhang","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiat."},{"key":"10.1016\/j.bbi.2020.08.028_b0780","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.schres.2019.08.005","article-title":"The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia","volume":"212","author":"Zhang","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2020.08.028_b0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2019.07.002","article-title":"Potential role of melatonin in autoimmune diseases","volume":"48","author":"Zhao","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbi.2020.08.028_b0790","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpsychires.2017.04.004","article-title":"Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"92","author":"Zheng","year":"2017","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.bbi.2020.08.028_b0795","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acps.12862","article-title":"N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"137","author":"Zheng","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbi.2020.08.028_b0800","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.schres.2018.01.017","article-title":"Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"197","author":"Zhu","year":"2018","journal-title":"Schizophr. Res."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159120311557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159120311557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:07:36Z","timestamp":1760170056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159120311557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":160,"alternative-id":["S0889159120311557"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2020.08.028","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders \u2013 A comprehensive systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2020.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}